J&J's Ortho Biotech Inks 5-Year CRADA with NCI to Develop Cancer Immunotherapies

Under the CRADA, Ortho Biotech, a unit of J&J's Centocor, will have an option to exclusively license new inventions developed jointly or independently by NCI scientists. The collaboration will focus on engineering patients' T-cells to treat melanoma and possibly other types of cancers.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.